Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IGM BIOSCIENCES, INC.

(IGMS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
71.62(c) 67.78(c) 68.36(c) 70.52(c) 74.82(c) Last
103 388 110 978 123 061 201 875 253 296 Volume
-1.23% -5.36% +0.86% +3.16% +6.10% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -170 M - -
Net cash position 2021 230 M - -
P/E ratio 2021 -14,7x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -226 M - -
Net cash position 2022 354 M - -
P/E ratio 2022 -11,7x
Yield 2022 -
Capitalization 2 399 M 2 399 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 144
Free-Float 45,4%
More Financials
Company
IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM... 
More about the company
Ratings of IGM Biosciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about IGM BIOSCIENCES, INC.
09/07IGM Biosciences to Participate in Three Upcoming Investor Conferences
GL
08/26IGM BIOSCIENCES : Morgan Stanley Starts IGM Biosciences at Overweight With $100 ..
MT
08/16IGM BIOSCIENCES : Wedbush Lifts IGM Biosciences' Price Target to $82 From $77; N..
MT
08/10IGM BIOSCIENCES : RBC Capital Adjusts IGM Biosciences PT to $110 From $107, Main..
MT
08/10IGM BIOSCIENCES : Posts Wider Q2 Loss; Files for Up to $400 Million Mixed-Securi..
MT
08/09IGM BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financial..
AQ
08/09IGM BIOSCIENCES : Announces Second Quarter 2021 Financial Results and Provides C..
AQ
08/09IGM BIOSCIENCES : Management's Discussion and Analysis of Financial Condition an..
AQ
08/09Igm Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended J..
CI
08/04IGM BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/04IGM Biosciences, Inc. Announces Management Changes
CI
07/30SECTOR UPDATE : Health Care Stocks Scratching Out Small Advance Just Ahead of Fr..
MT
07/30SECTOR UPDATE : Health Care Stocks Posting Modest Friday Advance
MT
07/29IGM BIOSCIENCES : Names New Chief Medical Officer
MT
07/29IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., ..
GL
More news
News in other languages on IGM BIOSCIENCES, INC.
2019IGM BIOSCIENCES : en hausse, boosté par un analyste
2019IGM BIOSCIENCES : Jefferies commence à l'achat
More news
Analyst Recommendations on IGM BIOSCIENCES, INC.
More recommendations
Chart IGM BIOSCIENCES, INC.
Duration : Period :
IGM Biosciences, Inc. Technical Analysis Chart | IGMS | US4495851085 | MarketScreener
Technical analysis trends IGM BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 74,82 $
Average target price 103,00 $
Spread / Average Target 37,7%
EPS Revisions
Managers and Directors
Fred M. Schwarzer President, Chief Executive Officer & Director
Misbah Tahir Chief Financial Officer
Michael D. Loberg Chairman
Bruce A. Keyt Chief Scientific Officer
T. S. Harigopal Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
IGM BIOSCIENCES, INC.-15.26%2 399
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850